Stockscreener 앱 받기
10.57
2.32%
0.24
시간 외 거래:
10.49
-0.08
-0.76%
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Tango Therapeutics stock hits 52-week high at 9.7 USD By Investing.com - Investing.com Nigeria
Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal TestingBuy (TNGX) - Seeking Alpha
Wall Street Analysts See a 46.07% Upside in Tango Therapeutics (TNGX): Can the Stock Really Move This High? - Finviz
Tango Therapeutics launches $100M at-the-market stock offering - MSN
Tango Therapeutics launches new $100 million at-the-market stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc files for mixed shelf offeringSEC filing - MarketScreener
Tango Therapeutics files prospectus for resale of 1.7 million shares by selling stockholderSEC filing - MarketScreener
Tango Therapeutics launches new $100 million at-the-market stock offering - Investing.com Nigeria
Tango Therapeutics Enters New Sales Agreement with Leerink - TipRanks
[S-3] Tango Therapeutics, Inc. Shelf Registration Statement | TNGX SEC FilingForm S-3 - Stock Titan
[8-K] Tango Therapeutics, Inc. Reports Material Event | TNGX SEC FilingForm 8-K - Stock Titan
Tango Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Why Tango Therapeutics Inc. stock remains on watchlists2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Short interest data insights for Tango Therapeutics Inc.Weekly Trade Review & Accurate Intraday Trade Tips - newser.com
How analysts rate Tango Therapeutics Inc. stock todayWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
TNGX: Pivotal pancreatic cancer study advances, with strong combo data and cash runway into 2028 - TradingView
Will Tango Therapeutics Inc. stock benefit from automationForecast Cut & Short-Term Trading Alerts - newser.com
TNGX: Vopimetostat advances in pivotal and combo studies, with strong efficacy and cash runway into 2028 - TradingView
Long term hold vs stop loss in Tango Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - newser.com
Why Tango Therapeutics Inc. is moving todayPortfolio Return Report & Free Reliable Trade Execution Plans - newser.com
Wolfe Research Initiates Coverage of Tango Therapeutics (TNGX) with Peer Perform Recommendation - Nasdaq
B. Riley Securities Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Wolfe Research Initiates Coverage on Tango Therapeutics (TNGX) | - GuruFocus
Tango Therapeutics price target raised to $14 from $8 at B. Riley - TipRanks
B. Riley Adjusts Price Target on Tango Therapeutics to $14 From $8, Maintains Buy Rating - MarketScreener
Will Tango Therapeutics Inc. stock maintain dividend yieldInsider Selling & Reliable Breakout Forecasts - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Macro Impact & Short-Term High Return Strategies - newser.com
Does Tango Therapeutics Inc. fit your quant trading modelMarket Growth Report & Daily Market Momentum Tracking - newser.com
Can Tango Therapeutics Inc. stock outperform in 2025 bull marketWeekly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
How Tango Therapeutics Inc. stock performs in rising dollar environment2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Will Tango Therapeutics Inc. stock attract ESG investorsMarket Rally & Daily Profit Maximizing Trade Tips - newser.com
Tango Therapeutics’ Promising Update on TNG260 Clinical Study - MSN
Tango Therapeutics (TNGX): Evaluating Valuation Following Strong Revenue Growth and Doubling Share Price - Yahoo Finance
0.53%
1.88%
자본화:
|
볼륨(24시간):